Abstract
Group 3 Pulmonary Hypertension commonly complicates idiopathic NSIP and is associated with adverse outcomes
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. King reports personal fees from Boehringer Ingelheim, personal fees from France Foundation for PILOT program, outside the submitted work.
Conflict of interest: Oksana A. Shlobin
Conflict of interest: Dr. Nargues Weir has no conflicts of interest to disclose.
Conflict of interest: Dr. Libre has nothing to disclose.
Conflict of interest: Dr. Franco-Palacios has nothing to disclose.
Conflict of interest: Dr. Ahmad has nothing to disclose.
Conflict of interest: SN is a consultant for, has received research funding and is on the speakers bureau for Boerhinger-Ingelheim, Gilead Sciences, Roche-Genentech, Bayer Pharmaceuticals and United Therapeutics. He is also a consultant for Bellerophon.
Conflict of interest: Dr. Brown has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018